Glutamine PET Imaging Colorectal Cancer
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 6 people enrolled
- Started
- 27 Apr 2021
- Ended
- 23 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Carbon C 11 Glutamine
- Fluorine F 18 L-glutamate Derivative BAY94-9392
- Positron Emission Tomography
- Blood Draw
- Record updated
- 2 January 2026
- Why it stopped
- \<75% participation
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ≥18 years of age
- Pathologically or cytologically confirmed diagnosis of metastatic (Stage IV) RAS wildtype CRC
- Eligible for anti-EGFR monoclonal antibody (mAb) therapy as standard-of-care (SOC), either as a single agent or in combination with approved SOC therapies or investigational agents as part of IRB-approved clinical trials
- Archived tissue from the CRC primary tumor in sufficient amounts to allow RNA-seq gene analysis; specimen from metastatic sites are not required but highly preferred
- Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a standard-of-care procedure within 28 days of baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- At least one lesion >2 cm in diameter and thus will be measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0 to avoid PET partial volume effects
- Ability to provide written informed consent in accordance with institutional policies
Who cannot take part
- Any other current or previous malignancy within the past 5 years
- Previous EGFR-directed therapy
- Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
- Pregnant or lactating females
Where in United States
- M D Anderson Cancer CenterHouston, United States
About the trial
What the trial wants to find out
The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
The group in the trial
- TreatmentTreatment being tested
Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
Treatment: Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography, and Blood Draw
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Glutamine PET Imaging of Colorectal Cancer
- Record updated
- 2 January 2026